Serum total IgG, IgA, IgM, IgD, and IgE concentrations, heterophil antibody titer, Epstein-Barr virus (EBV)-specific antibodies titer, and hematologic changes were studied longitudinally in 19 patients with EBV-induced infectious mononucleosis who were followed up for 1.5–34 months. In 9 patients, the changes in these variables were compared with baseline data on a pre-illness serum sample. All 5 immunoglobulins (Ig) showed a significant rise during the acute illness followed by a drop during convalescence, and a gradual ‘normalization’ within several months to a year. On the average, IgE peaked to 276% during the first week, IgM to 176% at about 10 days, IgA to 154% at 15–20 days, IgG to 135% at 10–15 days, and IgD to 141% during the first 2 months after onset. IgE and IgM levels were significantly suppressed during convalescence by an average of about 40 and 25% of pre-illness level, respectively. A relationship was noted between Ig rise and the increase in circulating atypical lymphocytes. The data clearly demonstrate the polyclonal nature of Ig production during the acute phase of EBV-induced mononucleosis, with a striking and early reactivity of IgE.

This content is only available via PDF.
© 1984 S. Karger AG, Basel
1984
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.